TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05278819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity elevation
Description: 5 repetitions of active upper extremity elevation in a sitting position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity elevation
Description: 5 repetitions of active upper extremity elevation in a sitting position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity elevation with deep breathing
Description: 5 repetitions of active upper extremity elevation with deep breathing in a sitting position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity elevation with deep breathing
Description: 5 repetitions of active upper extremity elevation with deep breathing in a sitting position
Study: NCT05997628

Intervention type: OTHER
Intervention: Detection of NAD+/NADH concentration of Peripheral Blood Samples
Description: Peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels, hematology, blood biochemical indicators, immune cells and SIRT1 level in peripheral blood in different age groups. This experiment monitors indicators mentioned above without any drug intervention.

Intervention type: OTHER
Intervention: Detection of NAD+/NADH concentration of Peripheral Blood Samples
Description: Peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels, hematology, blood biochemical indicators, immune cells and SIRT1 level in peripheral blood in different age groups. This experiment monitors indicators mentioned above without any drug intervention.

Intervention type: OTHER
Intervention: Detection of NAD+/NADH concentration of Peripheral Blood Samples
Description: Peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels, hematology, blood biochemical indicators, immune cells and SIRT1 level in peripheral blood in different age groups. This experiment monitors indicators mentioned above without any drug intervention.
Study: NCT06238635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobolimab
Description: Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobolimab
Description: Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.
Study: NCT06319742

Intervention type: DIAGNOSTIC_TEST
Intervention: Extracellular vescicles (EV) analysis
Description: The patients undergo a blood sample for EV analyses: EVs will be characterized by nanoparticle tracking analysis, western blot, bead-based flow cytometry (direct and inverse approach), and ELISA.~We will evaluate diameter and concentration of serum nanoparticles (NPs) by nanoparticle tracking analysis (NTA) using NanoSight LM10. Western Blot analysis will be performed on protein lysate after EV immuno-capture (using beads covered with antibodies against EV specific tetraspanins, CD9, CD63 and CD81). EV profiling will be performed using a standardized multiplex bead-based flow cytometric assay, using MACSPlex Human Exosome Kit (Miltenyi Biotec; Bergisch Gladbach, Germany), as previously described. 22 The detection of 37 different surface antigens commonly expressed on EV membrane (including markers from activated platelets, endothelium, and inflammatory cells) will be simultaneously performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Extracellular vescicles (EV) analysis
Description: The patients undergo a blood sample for EV analyses: EVs will be characterized by nanoparticle tracking analysis, western blot, bead-based flow cytometry (direct and inverse approach), and ELISA.~We will evaluate diameter and concentration of serum nanoparticles (NPs) by nanoparticle tracking analysis (NTA) using NanoSight LM10. Western Blot analysis will be performed on protein lysate after EV immuno-capture (using beads covered with antibodies against EV specific tetraspanins, CD9, CD63 and CD81). EV profiling will be performed using a standardized multiplex bead-based flow cytometric assay, using MACSPlex Human Exosome Kit (Miltenyi Biotec; Bergisch Gladbach, Germany), as previously described. 22 The detection of 37 different surface antigens commonly expressed on EV membrane (including markers from activated platelets, endothelium, and inflammatory cells) will be simultaneously performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Extracellular vescicles (EV) analysis
Description: The patients undergo a blood sample for EV analyses: EVs will be characterized by nanoparticle tracking analysis, western blot, bead-based flow cytometry (direct and inverse approach), and ELISA.~We will evaluate diameter and concentration of serum nanoparticles (NPs) by nanoparticle tracking analysis (NTA) using NanoSight LM10. Western Blot analysis will be performed on protein lysate after EV immuno-capture (using beads covered with antibodies against EV specific tetraspanins, CD9, CD63 and CD81). EV profiling will be performed using a standardized multiplex bead-based flow cytometric assay, using MACSPlex Human Exosome Kit (Miltenyi Biotec; Bergisch Gladbach, Germany), as previously described. 22 The detection of 37 different surface antigens commonly expressed on EV membrane (including markers from activated platelets, endothelium, and inflammatory cells) will be simultaneously performed.
Study: NCT05778942

Intervention type: DEVICE
Intervention: Eyestil SYNFO
Description: Instillation of study drug in both eyes: preservative-free ophthalmic solution based on sodium hyaluronate and xanthan gum
Study: NCT05260879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes prevention program
Description: Adaptation of the Centers for Disease Control and Prevention (CDC) Diabetes Prevention Program Power to Prevent for use in low income neighborhoods in Bamako, Mali

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes prevention program
Description: Adaptation of the Centers for Disease Control and Prevention (CDC) Diabetes Prevention Program Power to Prevent for use in low income neighborhoods in Bamako, Mali
Study: NCT05866042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.
Study: NCT05616299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrightPoint
Description: Data from the BrightPoint device during epidural placement will be collected in real time on a tablet with pre-programmed software including tissue color and light reflectance with time stamps of when epidural space is entered as voiced by clinician per LOR.
Study: NCT04968431

Intervention type: OTHER
Intervention: 2D Echocardiography
Description: Mitral valve area will be determined by 2 D echo-Doppler methods

Intervention type: OTHER
Intervention: 3D Echocardiography
Description: Patients included in the study will undergo 3D Echo after being evaluated with 2D Echo. Mitral valve area will be determined by real time 3D.
Study: NCT04701723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac coherence
Description: standard care associated to cardiac coherence training during 3 months
Study: NCT06001645

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and bronchoalveolar fluid collection and analysis
Description: Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CT scan
Description: Computed Tomography Scan per normal clinical practice
Study: NCT04763226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986308
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (for BMS-986308)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Specified dose on specified days
Study: NCT06240819

Intervention type: OTHER
Group type: OTHER
Intervention: Sleeper Stretch
Description: They will receive three sessions a week for four weeks. In a session three sets with three repetitions of sleeper stretch in a side lying position

Intervention type: OTHER
Group type: OTHER
Intervention: Cross Body Stretch
Description: They will receive three sessions a week for four weeks. In a session, three sets with three repetitions of cross-body stretch will be done in sitting position.
Study: NCT05976139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subthreshold treatment with micropulsed laser
Description: The laser instrument used is the Q 577® Laser System, Iridex, wavelength 577 yellow. The standard pattern used is:~* Power: 5% Duty Cycle~* Power 250 mw~* Pulse duration 200 ms~* Spot size 100 micron~* Pattern spacing 0.0 confluente, griglie 7x7
Study: NCT06267144

Intervention type: DRUG
Intervention: Sintilimab plus chemotherapy
Description: Sintilimab: 200 mg via intravenous infusion on Day 1 of each 21-day cycle for 2-3 cycles in the neoadjuvant therapy and the maintenance therapy.~Chemotherapy drugs: carboplatin/cisplatin+Pemetrexed/gemcitabine/albuminpaclitaxel.~Carboplatin: AUC 5 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Pemetrexed: 500mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Gemcitabine:1.0g/m2 via intravenous infusion in day1 and day8, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly. Albuminpaclitaxel: 260 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.
Study: NCT05005962

Intervention type: DEVICE
Intervention: Neurothrombectomy
Description: Neurothrombectomy device will be used to treat patients experiencing the AIS due to large intracranial vessel occlusion within 8 hours of last known well to collect real-world data and to access clinical outcomes associated with the use of these devices.
Study: NCT06273813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine 15 MG/ML
Description: Single intravenous administration of Ketorolac Tromethamine injection in Cohort 1 on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Three doses of topical ketorolac tromethamine over the course of 1 day, 6 hours apart for each of 3 subsequent treatment periods in cohort 1 Three doses of Ketorolac Tromethamine, 6 hours apart, over the course of 5 days in cohorts 2 and 3
Study: NCT05463497

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: JW0201: single administration, Tablet, Oral, BID for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: JW0201: single administration, Tablet, Oral, BID for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: JW0201: single administration, Tablet, Oral, BID for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: JW0201: single administration, Tablet, Oral, BID for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: C2103: single administration, Tablet, Oral, BID for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: C2103: single administration, Tablet, Oral, BID for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: C2104 : single administration, Tablet, Oral, QD for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: C2104 : single administration, Tablet, Oral, QD for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment E
Description: JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment E
Description: JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days
Study: NCT06431529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor neoantigen specific T cell
Description: Isolate the patient's autologous monocytes, induce and culture them into tumor antigen presenting cells in vitro, and then phagocytose tumor tissue cells obtained from biopsy or surgery to present tumor neoantigens to autologous T cells. The final product For tumor neoantigen specific T cells (NeoT).
Study: NCT04708951

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOCUFF VISION® device
Description: ENDOCUFF VISION® is a disposable cap placed on the tip of a standard colonoscope, intended to flatten colonic folds and assist in controlling the colonoscope's field of view and tip positioning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EYE® colonoscope
Description: The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning
Study: NCT05963945

Intervention type: DEVICE
Intervention: Carebot AI CXR
Description: The proposed DLAD (Carebot AI CXR) is a deep learning-based medical device designed to assist radiologists in interpreting chest X-ray images acquired in anteroposterior (AP) or posteroanterior (PA) projection. By employing advanced deep learning algorithms, this solution enables automatic detection of abnormal findings by analyzing visual patterns associated with specific conditions. The targeted abnormalities include atelectasis (ATE), consolidation (CON), pleural effusion (EFF), pulmonary lesion (LES), subcutaneous emphysema (SCE), cardiomegaly (CMG), and pneumothorax (PNO). The DLAD functions as a prediction algorithm complemented by various application peripherals, such as web-based communication tools, DICOM file conversion capabilities, and storage and reporting libraries supporting both DICOM Structured Report and DICOM Presentation State formats.
Study: NCT05787327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb
Description: Yinqiaosan-Maxingganshitang granules

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05083910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Oxytocin administration
Description: Group I: Oxytocin( the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord). Group II:oxytocin plus intrauterine misoprostol (the oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity. Group III:100-mg carbetocin was intravenously administered immediately after birth of the baby.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Oxytocin administration
Description: Group I: Oxytocin( the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord). Group II:oxytocin plus intrauterine misoprostol (the oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity. Group III:100-mg carbetocin was intravenously administered immediately after birth of the baby.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Oxytocin administration
Description: Group I: Oxytocin( the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord). Group II:oxytocin plus intrauterine misoprostol (the oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity. Group III:100-mg carbetocin was intravenously administered immediately after birth of the baby.
Study: NCT05510050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe Vera Extract 1
Description: 2 capsules taken daily for 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 2 capsules taken daily for 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe Vera Extract 2
Description: 2 capsules taken daily for 30 days
Study: NCT05442684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
Description: Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O-IH

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-based COVID-19 vaccine
Description: Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of mRNA-based COVID-19 vaccine
Study: NCT04687904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Description: Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).